Roche CEO says Novo's Catalent buyout 'could be a problem' for smaller drugmakers

While Novo Holdings and Catalent continue to voice confidence that their planned $16.5 billion merger will go through before the year is out, the deal has received near-constant criticism over the past several weeks. 

Now, a new complaint has surfaced—not from lawmakers or consumer groups but a major pharma CEO.